The discriminative stimulus effects of naloxone and naltrexone in morphine-treated rhesus monkeys: Comparison of oral and subcutaneous administration

Psychopharmacology

Volumn 144, Issue 2, 1999, Pages 131-136

  Gauthier, Cheryl A ^a   France, Charles P ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Drug discrimination; Naloxone; Naltrexone; Oral; Rhesus monkey; SC

Indexed keywords

DIAMORPHINE; NALOXONE; NALTREXONE; OPIATE ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; DISCRIMINATION LEARNING; DISCRIMINATIVE STIMULUS; DRUG ABUSE; DRUG DEPENDENCE; DRUG DISCRIMINATION; DRUG POTENCY; HYPOTHESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHESUS MONKEY; STIMULUS RESPONSE; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; DISCRIMINATION LEARNING; FEMALE; MACACA MULATTA; MALE; MORPHINE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS;

EID: 0033032868     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050985     Document Type: Article

References (15)

1. Bashaw ED, Kaiko RF, Grandy RP, Reder RF, Goldenheim PD (1995) Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade. Int J Clin Pharmacol Ther 9:524-529
2. Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, Foley K, Houde RW, Marsh F, Kreek MJ (1992) Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 1:90-95
3. Culpepper-Morgan JA, Holt PR, LaRoche D, Kreek MJ (1995) Orally administered opioid antagonists reverse both mu and kappa opioid agonist delay of gastrointestinal transit in the guinea pig. Life Sci 14:1187-1192
4. France CP, Woods JH (1989) Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 250:937-943
5. France CP, Gerak LR, Flynn D, Winger GD, Medzihradsky F, Bagley JR, Brockunier LL, Woods JH (1995) Behavioral effects and receptor binding affinities of fentanyl derivatives in rhesus monkeys. J Pharmacol Exp Ther 274:17-28
6. Gonzalez JP, Brogden RN (1988) Naltrexone, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35:192-213
7. Inturrisi CE (1976) Disposition of narcotics and narcotic antagonists. Ann N Y Acad Sci 281:273-287
8. Kastrup EK, Hebel SK, Threlkeld DS, Bell WL, Huenefeld LG, Neubauer DJ, Pier TA, Thomas OL (eds) (1997) Facts and comparisons. Wolters Kluwer, St Louis
9. McEvoy GK, Litvak K, Welsh OH (eds) (1996) American Hospital Formulary Service Drug Information. American Society of Health-System Pharmacists, Bethesda
10. Ngai SH, Berkowitz BA, Yang JC, Hempstead J, Spector S (1976) Pharmacokinetics of naloxone in rats and in man. Anesthesiology 44:398-401
11. Reisine T, Pasternak G (1996) Opioid analgesics and antagonists. In: Hardman JG, Limbard LE, Molinoff PB, Ruddon RW, Goodman Gilman A (eds) Goodman and Gilman's the pharmacological basis of therapeutics, 9th. McGraw Hill, New York, pp 521-555
12. Resnick RB, Volaka J, Freedman A.M, Thomas M (1974) Studies of EN-1639 A (naltrexone): a new narcotic antagonist. Am J Psychiatry 131:646-650
13. Stitzer ML, Eissenberg T, Johnson RE, Liebson IA (1997) Acute dependence in humans; the relative potency of naloxone and naltrexone in precipitated withdrawal. In: Harris LS (ed) Proceedings of the College on Problems of Drug Dependence: National Institute on Drug Abuse Research. US Government Printing Office, Washington, D.C., Monograph 174:86
14. Wall M E, Brine DR, Perez-Reyes M (1981) Metabolism and disposition of naltrexone in man after oral and intravenous administration. Drug Metab Dispos 9:369-375
15. Zaks A, Jones T, Fink M, Freedman AM (1971) Naloxone treatment of opiate dependence. JAMA 215:2108-2110